相关实验视频
Updated: Mar 12, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
从延长诱导的经验教训和改善tofacitinib治疗性结肠炎的实际证据
Yasser Fouad1, Ahmed S Aboelela2
1Department of Gastroenterology and Endemic Medicine, Faculty of Medicine, Minia University, Minia 19111, Egypt. yasserfouad10@yahoo.com.
延长托法西提尼布诱导治疗性结肠炎 (UC) 超过八周,对许多患者显示出显著的益处. 这种方法可以在超过一半的中度至重度UC病例中带来缓解,并且具有良好的安全性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 治疗正在使用像托法西提尼布这样的简氏激酶 (JAK) 抑制剂发展.
- 响应异质性仍然是UC管理的一个重大挑战.
- 托法西提尼布提供快速开始和口服方便,但需要优化治疗策略.
研究的目的:
- 审查关于延长托法西提尼布诱导治疗UC的现实世界的证据.
- 突出从长期诱导策略中学到的经验教训.
- 为UC患者量身定制的治疗决策提供一个框架.
主要方法:
- 对近期关于托法西提尼布诱导的现实世界证据的分析.
- 综述多中心,52周的现实研究.
- 检查影响治疗结果的因素,包括吸烟和先前的生物暴露.
主要成果:
- 超过一半的中度至重度UC患者在16周的长期托法西提尼布诱导后实现了缓解.
- 观察到持续缓解和良好的安全性.
- 吸烟和先前的生物暴露影响了结果和维持剂量.
结论:
- 延长托法西提尼布诱导疗法可以显著有利于UC患者的一个子集.
- 响应引导的诱导范式,而不是固定的持续时间,得到了机械学发现的支持.
- 延长诱导是一种以患者为中心的策略,以最大限度地提高托法西替尼对长期UC缓解的潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

